EYEN Eyenovia Inc.: קפיטליזציה חשבונאית

Eyenovia, Inc. (EYEN) business growth relies on the implementation of the Optejet contactless drug delivery method, the promotion of Clobetasol and Mydcombi, and myopia treatment trials in children. However, the company faces a cash shortage as system launch costs exceed revenues, necessitating external financing. The current figure is -0.01. This price action chart demonstrates the potential of the biopharmaceutical company, which possesses patent-protected technology and high margins.

Professional managers utilize fundamental filters to assess the real value of assets, where book capitalization determines the volume of equity through the market value of net assets on a daily basis. For Eyenovia, Inc. (EYEN), which invests in a staff of ophthalmologists and engineers to develop microdosing, the dynamics of the book capital structure reflect the efficiency of innovation capitalization and the market's readiness for the launch of new products.